SureTrader
Home > Boards > Other Markets > Foreign Stock Markets >

Antisoma (LSE:ASM)

LSE:ASM RSS Feed
Add LSE:ASM Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 11/2/2010 2:51:03 PM - Followers: 1 - Board type: Free - Posts Today: 0

Antisoma is a biotechnology company specialising in the development of novel drugs for the treatment of cancer.

Antisoma has a diverse portfolio of drugs in development / pipeline

The Company was founded in 1988 and its shares are traded on the London Stock Exchange. Antisoma is based at offices in London and Cambridge, MA.

 

Head office

Antisoma Research Limited
Building 5
Chiswick Park
566 Chiswick High Road
London
W4 5YF

IR contacts

 Alison Saville
Tel: +44 (0) 20 3249 2100
Fax: +44 (0) 20 3249 2101
enquiries@antisoma.com


AS1413 (amonafide L-malate, formerly Xanafide®)

AS1413 is a DNA intercalator that induces apoptotic signalling by blocking TopoII binding to DNA. Unlike classical TopoII inhibitors, a distinctive feature of AS1413 is its ability to evade PgP and related transporters responsible for multi-drug resistance. AS1413 is currently in phase III development in secondary AML.

Secondary AML (acute myeloid leukaemia)

AML is divided into two major categories, de-novo and secondary. AML is classified as secondary AML if it occurs as a result of a prior haematological disease or treatment with chemotherapy or radiation therapy or a combination of the two causes. In a phase II trial, treatment with AS1413 plus cytarabine resulted in a complete response rate of 38.6%, with an additional 3.4% showing CRi (complete response without recovery of blood cell count). This compares with CR rates of around 25% seen with standard treatment in similar AML patients enrolled in two large American studies. AS1413 is now in a phase III registration trial called ACCEDE. The ACCEDE trial compares AS1413 plus cytarabine with daunorubicin plus cytarabine in 450 patients

 Latest presentation

AS1413 is distinct from daunorubicin and etoposide, poster presentation at AACR, Washington 2010

Pgp impacts on CR rates in AML, poster presentation at ASCO, Chicago 2010

 

 AS1411 

AS1411 has shown activity against a wide range of solid and blood cancer cell lines in preclinical experiments and could therefore have potential against a variety of human cancers. Clinical development is focused on acute myeloid leukaemia (AML).

AS1411 is an aptamer. This is a type of drug based on a short piece of DNA or RNA. However, unlike some other drugs based on these chemicals, aptamers work as conventional drugs, binding to a protein target by virtue of a fit with its three-dimensional structure. The term aptamer is derived from the Greek ‘aptos’ (to fit).

AS1411 has a structure that allows it to bind specifically to a protein called nucleolin, which is found on the surface of many cancer cells. Once bound, the AS1411 aptamer is taken into the cancer cell, where it causes death by apoptosis (programmed cell death).

A previous phase I trial of AS1411 in 30 patients with various advanced cancers reported no serious adverse events related to treatment and promising signs of anti-cancer activity were seen.

 Latest presentations

AS1411 novel combinations and microarray, poster presentation at AACR, Washington 2010

Long-term outcomes of patients responding to AS1411 regimen, poster presentation at ASCO, Chicago 2010

 

ASA404

ATTRACT-1 phase III trial of ASA404 halted following interim analysis

 

29 March 2010, London, UK, and Cambridge, MA: www.antisoma.com/asm/media/press/pr2010/2010-03-29/

Antisoma plc (LSE: ASM; USOTC: ATSMY) announces that the planned interim analysis of data from the ATTRACT-1 phase III trial of ASA404 in previously untreated non-small cell lung cancer (NSCLC) has shown that continuation of the trial would be futile, as there is little or no prospect of demonstrating a survival benefit with ASA404 in this setting. The ATTRACT-1 trial will therefore be halted.

 


Press releases 2010

 

Date Title    
03/06/2010 Antisoma's AS1413 gains FDA Fast Track status for treatment of secondary acute myeloid leukaemia    
21/05/2010 Antisoma to present at the Citi Investment Research Global Health Care Conference    
17/05/2010 Antisoma Interim Management Statement    
19/04/2010 AACR presentations highlight potential of Antisoma drugs AS1413 and AS1411    
29/03/2010 ATTRACT-1 phase III trial of ASA404 halted following interim analysis    
18/03/2010 Antisoma initiates phase IIb trial of AS1411 in acute myeloid leukaemia    
18/02/2010 Antisoma reports half-year results    
02/02/2010 Antisoma to present at BIO CEO Conference    
07/01/2010 Antisoma to present at J.P. Morgan Healthcare Conference    

June 2010

06/03/2010 Antisoma's AS1413 gains FDA Fast Track status for treatment of secondary acute myeloid leukaemia

06/04/2010 Antisoma to present at 9th Annual Needham Life Sciences Conference and 4th Annual Jefferies Healthcare Conference in New York

06/05/2010 Antisoma announces presentation at ASCO of new data supporting AS1413 and AS1411

06/14/2010 Antisoma announces AS1413 and AS1411 presentations at EHA

 

 


 Annual Report 2009

www.antisoma.com/asm/ir/reports/rep2009/ar2009/ar2009.pdf

 


 Partnering opportunities

Antisoma is looking for worldwide partners for the following products:

AS1413 A novel DNA intercalator in phase III for secondary AML

AS1411 A novel DNA aptamer in phase IIb for relapsed/refractory AML

AS1402 A humanised monoclonal antibody (huHMFG1) which targets the glycoprotein, MUC1, that is overexpressed and aberrantly glycosylated in the majority of epithelial tumors. Phase II data are available

AS1409 A fusion protein combining the anti-tumour cytokine IL-12, with the tumour-targeting antibody BC1. A phase I trial with AS1409 in patients with malignant melanoma and renal cell carcinoma has been completed

PPM1D Inhibitor Programme PPM1D is aberrantly amplified in a range of cancers. Activation results in negative regulation of p53 function and other tumour suppressor pathways. Additional functions include the regulation of the base excision pathways of DNA repair. Programme is at lead optimisation

Dendritic Cell Autoimmune Modulators (DCAM) A novel class of oral agents that target specific populations of dendritic cells to modulate the immune response

 


LONDON: 

  

 

 

 

 

FRANKFURT: 

 

 

USOTC:

 

 

 


 

06/02, 2010: 5,05 GBp

06/03, 2010: 6,10 GBp ( +20,79%)     Board Created @ 5,85 GBp

 


 

 Do your own DD & trade smart

 ADR program

www.antisoma.com/asm/ir/shareinfo/adr/

Antisoma has a Level One American Depositary Receipt (ADR) Program.

This will enable US investors in Antisoma to trade in a dollar-denominated security and is intended as a step towards a full listing of Antisoma's shares on NASDAQ.

Trading symbol: ATSMY
CUSIP number: 03718Q109

Ratio: 1 ADR : 20 Ordinary Antisoma shares

Antisoma has appointed The Bank of New York as the depositary bank for our ADR Program.

For more information please contact the Bank of New York:

Telephone from UK: 001 212 815 3700
Telephone from US: 1 888 269 2377 (1 888 BNY ADRS)
Email: shareowners@bankofny.com
www.bankofny.com

 

SureTrader
LSE:ASM
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#69   ATSMY S1.88! mlkrborn 11/02/10 02:51:03 PM
#68   oha...lmao.. peewee 09/10/10 07:11:52 PM
#67   Antisoma's phase III trial of AS1413 completes patient enrolment califax 09/10/10 04:57:34 PM
#66   Antisoma to present at Canaccord Global Growth Conference califax 08/06/10 09:48:08 AM
#65   Antisoma's preliminary results for the year ended 30 califax 07/31/10 09:05:34 AM
#63   Any News here ? :-) peewee 07/24/10 05:38:48 PM
#62   Notification of Preliminary Results califax 07/22/10 05:21:13 AM
#61   IR contacts califax 06/15/10 08:09:26 AM
#60   Antisoma announces AS1413 and AS1411 presentations at EHA califax 06/14/10 07:10:37 AM
#59   4th Annual Jefferies Healthcare Conference (06/11/10) califax 06/10/10 01:34:27 PM
#58   9th Annual Needham Life Sciences Conference (06/10/10) califax 06/09/10 11:01:36 AM
#57   Antisoma Daily Value traded ! (Grafic now working) peewee 06/07/10 04:58:11 PM
#56   Static CHART, imo its just starting... peewee 06/07/10 04:55:25 PM
#54   Change 1.55 (22.96%) peewee 06/07/10 08:24:18 AM
#53   Change 1.25 (18.52%) peewee 06/07/10 04:17:39 AM
#52   Presentations from the Leukemia session at ASCO (part1) califax 06/06/10 06:48:33 AM
#51   Antisoma announces presentation at ASCO of new data_supporting_AS1413_and_AS1411 califax 06/05/10 09:17:57 AM
#50   Ax man ; Cool ..very helpfull indeed. Thnx.. mlkrborn 06/05/10 09:02:06 AM
#49   ASCO - Saturday June 5, califax 06/05/10 06:37:55 AM
#48   Someone must email to the IR and tell peewee 06/04/10 07:49:44 AM
#47   EDIT(it can only be that then ax ?): peewee 06/04/10 07:36:21 AM
#46   9th Annual Needham Healthcare Conference peewee 06/04/10 07:34:29 AM
#45   Antisoma to present at 9th Annual Needham Life califax 06/04/10 07:23:32 AM
#44   Bid 7.05 Ask 7.30 peewee 06/04/10 07:11:43 AM
#43   ASCO 2010 - Poster Sessions by Antisoma califax 06/04/10 06:53:46 AM
#42   FDAnews Drug Daily Bulletin peewee 06/04/10 06:53:10 AM
#40   04 Jun 2010 - Antisoma plc announced hat peewee 06/04/10 06:45:16 AM
#39   http://www.bionity.com/news/e/118512/?WT.mc_id=ca0068 peewee 06/04/10 06:43:23 AM
#38   http://www.medicalnewstoday.com/articles/190778.php peewee 06/04/10 06:39:03 AM
#37   ASCO Trials in Progress Poster Session 06/07,2010 califax 06/04/10 06:32:42 AM
#36   ASCO General Poster Session 06/05,2010 califax 06/04/10 06:28:46 AM
#35   Bid 7.05 Ask 7.10 peewee 06/04/10 06:26:05 AM
#34   ASCO General Poster Session 06/07,2010 califax 06/04/10 06:24:50 AM
#33   http://www.proactiveinvestors.com/companies/news/6296/antisomas-novel-leukaemia- peewee 06/04/10 06:24:10 AM
#32   ASCO Trials in Progress Poster Session 06/07,2010 califax 06/04/10 06:20:27 AM
#29   Bid 7.00 / Ask 7.05 peewee 06/04/10 05:36:11 AM
#28   Intraday peewee 06/04/10 04:27:05 AM
#27   Chart.. peewee 06/04/10 04:23:57 AM
#26   Bid 6.80 / Ask 7.00 peewee 06/04/10 04:01:59 AM
#25   Antisoma Interim Management Statement califax 06/04/10 03:50:15 AM
#22   Hey ax..we have the ASCO now with how peewee 06/03/10 07:15:02 PM
#21   IBOX updated (today) califax 06/03/10 02:49:53 PM
#20   is PPS in pence or dollars? Where is mlkrborn 06/03/10 02:41:17 PM
#19   Hehehe...just have seen that Error in the Quote...LOL ! peewee 06/03/10 01:02:08 PM
#18   Antisoma (LSE:ASM) califax 06/03/10 01:00:53 PM
#17   Antisoma (LSE:ASM) peewee 06/03/10 12:34:14 PM
#16   Looking great !!! peewee 06/03/10 10:34:37 AM
#15  Restored Changed Ticker to ASM peewee 06/03/10 09:50:50 AM
#14   www.wsw.com/webcast/rrshq17/asm.ln/2__Slide19.JPG peewee 06/03/10 08:31:28 AM
#13   Partnering conferences peewee 06/03/10 07:41:50 AM
PostSubject